July 30, 2021 - ROSEN LOGO.jpg
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
15 nov. 2023 20h10 HE | The Rosen Law Firm PA
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta...
July 30, 2021 - ROSEN LOGO.jpg
SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
01 nov. 2023 21h37 HE | The Rosen Law Firm PA
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta...
logo.jpg
iTeos Therapeutics Strengthens Leadership Team  
09 juin 2020 07h00 HE | iTeos Therapeutics SA
iTeos Therapeutics Strengthens Leadership Team   Matthew Gall joins as Chief Financial OfficerDr. Yvonne McGrath joins as Vice President of R&DPhilippe Brantegem joins as Vice President of Human...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Sarepta Therapeutics, and Canada Goose and Encourages Investors to Contact the Firm
25 sept. 2019 20h06 HE | Bragar Eagel & Squire
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics, Inc....
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm
18 sept. 2019 20h01 HE | Bragar Eagel & Squire
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....